Aiqin He
Overview
Explore the profile of Aiqin He including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li H, Xu Y, Jiao X, Xu Q, Peng Z, Tang Y, et al.
Med
. 2025 Jan;
100573.
PMID: 39827881
Background: It remains unclear whether adding CTLA-4 blockade to PD-1/PD-L1 blockade improves clinical outcomes in cervical cancer (CC). Methods: In this randomized, double-blind, placebo-controlled, phase 2 study (ClinicalTrials.gov: NCT04590599), patients...
2.
Wu X, Liu J, An R, Yin R, Zhang Y, Zhou H, et al.
J Gynecol Oncol
. 2024 Jun;
35(5):e99.
PMID: 38872480
Objective: First-line bevacizumab plus carboplatin and paclitaxel (CP) is approved for stage III/IV ovarian cancer treatment following initial surgical resection, based on global phase III GOG-0218 and ICON7 trials. This...
3.
Li X, Ou C, He A
Medicine (Baltimore)
. 2024 Apr;
103(14):e37680.
PMID: 38579053
To explore the analytical worth of prognostic nutritional index (PNI) and neutrophil-to-lymphocyte ratio (NLR) in patients with cervical squamous cell carcinoma. The clinical data of 539 patients with cervical cancer...
4.
He A, Shi C, Wu X, Sheng Y, Zhu X, Yang J, et al.
Diabetes Ther
. 2023 Nov;
15(1):201-214.
PMID: 37962825
Introduction: Diabetic kidney disease (DKD) has become the leading cause of chronic kidney disease and end-stage renal failure in most developed and many developing countries. Strategies aimed at identifying potential...
5.
Zhao M, Qiu S, Wu X, Miao P, Jiang Z, Zhu T, et al.
Target Oncol
. 2023 Oct;
18(6):869-883.
PMID: 37847485
Background: Poly (ADP-ribose) polymerase (PARP) inhibitors are a new maintenance therapy option for patients with ovarian cancer (OC). Objective: To evaluate the efficacy and influencing factors of the novel PARP...
6.
Hong X, Qiu S, Wu X, Chen S, Chen X, Zhang B, et al.
Drug Des Devel Ther
. 2023 Jul;
17:2025-2033.
PMID: 37435095
Purpose: Anlotinib is a novel oral small-molecule multi-target tyrosine kinase inhibitor that has been approved for treating non-small cell lung cancer. However, its efficacy and safety among patients with advanced...
7.
Shi C, Wan Y, He A, Wu X, Shen X, Zhu X, et al.
Acta Diabetol
. 2023 May;
60(9):1199-1207.
PMID: 37184672
Aims: Diabetic kidney disease (DKD) is the one of the leading causes of end-stage kidney disease. Unraveling novel biomarker signatures capable to identify patients with DKD is favorable for tackle...
8.
Ou C, Peng C, Wang Y, Lu S, Yu X, He Q, et al.
J Cancer
. 2023 May;
14(6):1011-1023.
PMID: 37151390
Ovarian cancer is the most malignant gynecological disease, which seriously threatens female physical and mental health. Paclitaxel is a first-line chemotherapy drug in the clinical treatment of ovarian cancer, but...
9.
Li Y, Zhu X, Zhang C, Yin Y, Chen L, Liu Y, et al.
Histol Histopathol
. 2023 May;
38(12):1487-1498.
PMID: 37140169
Overexpressed long noncoding RNA FTX is associated with low survival rate of epithelial ovarian cancer (EOC) patients, and enhances tumor infiltration. Thus, we aim to illuminate the undefined underlying mechanisms....
10.
Yin Y, Zhang L, Li Y, Zhang C, He A
J Ovarian Res
. 2023 Apr;
16(1):79.
PMID: 37085900
Objective: To detect the expression of Growth factor binding protein 2 associated binding protein 2 (Gab2) and CT10 regulator of kinase II (CrkII) in ovarian cancer and analyze their clinical...